Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Core Viewpoint - Defence Therapeutics Inc. is launching a private placement to raise up to $11,000,000 through the issuance of 20,000,000 units at a price of $0.55 per unit, each consisting of one common share and one warrant [1] Group 1: Private Placement Details - The private placement aims to raise aggregate gross proceeds of $6,000,000 (CAD) from two institutional investors, with proceeds deposited in escrow prior to closing [2] - Upon closing, the units will be released from escrow, and the investors' proceeds will be provided to the company in monthly cash tranches of $333,333 (CAD) over an 18-month period [2][3] - The company will release shares in equal monthly installments of approximately 606,060 shares over the 18-month term, contingent upon cash payments [3] Group 2: Warrant and Fee Structure - A total of 10,909,091 warrants will be issued, exercisable at $0.65 (CAD) per share for 24 months, with an equity blocker provision limiting ownership to 9.99% of outstanding shares [4] - Investors will receive a corporate finance fee of $360,000 (CAD), payable in cash or through the issuance of 654,546 units at the private placement price [5] Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [6] Group 4: Regulatory and Compliance Information - All securities issued under the private placement will be subject to resale restrictions in accordance with Canadian securities laws, with the closing expected around March 6, 2026, pending CSE approval [7]